Abstract: Compounds of Formula I and their uses of effective AXL inhibitors and for the treatment of physical condition mediated by AXL.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The present invention provides compounds of Formula (i). Furthermore, pharmaceutical compositions are provided comprising at least one compound of Formula (i), for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases.

Abstract: Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents.

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Abstract: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.

Abstract: The present disclosure relates to selective reduction of morphinan alkaloids in a continuous flow system. In particular, the present disclosure relates to selective reduction of thebaine or oripavine using hydrazine or a hydrazine-containing compound in a continuous flow system under elevated temperature and pressure condition to form 8,14-dihydrothebaine or 8,14-dihydrooripavine, respectively.

Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt as a medicament and for the treatment and/or prevention of pain.

Abstract: The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.

Abstract: The present invention relates to compounds of formula of formula I wherein X, L and R1 are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.

Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

Abstract: The present invention provides halichondrin analogs, such as compounds of Formula (I). The compounds may bind to microtubule sites, thereby inhibiting microtubule dynamics. Also provided are methods of synthesis, pharmaceutical compositions, kits, methods of treatment, and uses that involve the compounds for treatment of a proliferative disease (e.g., cancer). Compounds of the present invention are particularly useful for the treatment of metastatic breast cancer, non-small cell lung cancer, prostate cancer, and sarcoma. The included methods of synthesis are useful for the preparation of compounds of Formula (I)-(III) along with naturally occurring halicondrins (e.g., halichondrin B & C, norhalichondrin A, B, & C, and homohalichondrin A, B, & C). Also included are methods for interconverting between the halichondrins, norhalichondrins, and homohalichondrins and their unnatural epimers at the C38 ketal stereocenter through the use of an acid-mediated equilibration.

Abstract: The present invention relates to novel methods for the preparation of 1,3-benzodioxole heterocyclic compounds and intermediates for the same. The compounds are useful as PDE4 inhibitors.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.

Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.

Abstract: The present application provides salen indium catalysts of the following general structure wherein R is a coordinating alkoxide comprising at least one coordinating atom that forms a dative bond with In. The mononuclear salen indium catalysts are particularly useful in catalyzing ring-opening polymerizations of cyclic ester monomers, such as lactides. Also provided herein are methods of using the mononuclear salen indium complexes to catalyze polymerization of cyclic ester monomers. Of particular interest is the successful polymerization of lactides using the mononuclear salen indium catalysts to produce poly(lactic acid) having high isotacticity.

Abstract: Boron-based prodrugs of phenol- or aromatic hydroxyl group-containing therapeutic molecules (“original drugs”), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged retention (e.g., in a circulatory system) and, in particular, significantly lowered therapeutically effective dosage in order to reduce adverse effects while maintaining the desired therapeutic effects of the original drugs.

Abstract: It is possible to provide a composition that has absorption in a near infrared region and that can form a film having transparency in a visible region. Provided are a cured film, a near infrared ray absorption filter, a solid-state imaging device, an infrared sensor, and a compound. Provided is a composition including: a near infrared ray absorption substance of which a maximum absorption wavelength is in a wavelength range of 700 to 1,000 nm and a value obtained by dividing absorbance at a wavelength of 550 nm by absorbance at the maximum absorption wavelength is 0.015 or less. In the near infrared ray absorption substance, a half-width of the maximum absorption wavelength is preferably 60 nm or less. The near infrared ray absorption substance is preferably a compound having a pyrrolopyrrole skeleton and more preferably a pyrrolopyrrole boron compound.

Abstract: Alkali metal siliconates with low contents of water and alcohol are economically prepared in a three stage process where organoalkoxysilanes are reacted with a basic alkali metal salt to form an alcohol-rich hydrolysate, the hydrolysate is dried to a powder containing 0.5-5 wt. % alcohol, and residual alcohol is reduced in a post-treatment third step.

Abstract: The invention relates to a method of preparing monocyclic aromatic compounds from lignin and to the use of the method and/or the aromatic compounds obtained by the method according to the invention in the production of fuels, electronic components, plastic polymers, rubber, medicines, vitamins, cosmetic products, perfumes, foodstuffs, synthetic threads and fibres, synthetic leathers, adhesives, pesticides and fertilizers. The invention also relates to a method of producing fuels, electronic components, plastic polymers, rubber, medicines, vitamins, cosmetic products, perfumes, foodstuffs, synthetic threads and fibres, synthetic leathers, adhesives, pesticides and fertilizers, including a step of preparing aromatic compounds from lignin using the method according to the invention.

Abstract: The present invention concerns a method to access (E,Z)-7,9-dodecadienyl-1-acetate in two synthesis steps with excellent yields and selectivity greater than 70% by transformation of 2-hexenal into a novel intermediate, which is itself then transformed into (E,Z)-7,9-dodecandienyl-1-acetate.

Abstract: The present invention provides stable, cyclic bent allene metal complexes and methods of conducting chemical processes, preferably olefin hydrogenation, comprising contacting an olefin substrate, preferably an unsaturated polymer, with a cyclic bent allene metal complex as described herein, under hydrogenation conditions.

Abstract: Oxygen levels in biological tissue or systems can be measured by the phosphorescence quenching method using phosphorescent porphyrin probes, also referred to as a dendritic oxygen probes, with controllable quenching parameters and defined biodistributions. Provided are a “next generation” of oxygen sensors with substantially improved phosphorescence emission for better imaging capabilities, ease of use, increasing the quantum efficiency (phosphorescence intensity) and extending their range of applicability including constructing a class of oxygen sensors for making measurements in organic media. In addition, provided are methods for synthesizing new porphyrin constructs in which the porphyrin is made less flexible and more planar, changing with decrease internal quenching, and thereby increasing the phosphorescence emission used for oxygen sensing.

Abstract: A green route for preparing a metal organic framework include mixing metal precursor with a ligand precursor to form a solvent-free mixture; adding droplets of water to the mixture; heating the mixture at a first temperature after adding the water; and isolating the metal organic framework material including the metal and the ligand.

Abstract: A process for stabilizing lignin fibers, stabilized lignin fibers made by the process and carbonized fibers made from stabilized lignin fibers. The process includes heating lignin fibers to a temperature ranging from about 100° to about 220° C. while the fibers are in an atmosphere of air and HCl gas, generated as air is bubbled through concentrated hydrochloric acid for a period of time sufficient to stabilize the lignin fibers.

Abstract: The present invention relates to an alkyl glycoside sulfomethylsuccinate having the formula R1—O—Sn—R2 wherein R1 is an alkyl radical having 6 to 30 carbon atoms, S is a monosaccharide moiety, and R2 is a sulfomethylsuccinate moiety. Furthermore the present invention relates to a process for making this alkyl glycoside sulfomethylsuccinate and to an alkyl glycoside itaconate which is a useful intermediate for use in this process. Furthermore the present invention relates to a cosmetic composition comprising the alkyl glycoside sulfomethylsuccinate and to the use of the alkyl glycoside sulfomethylsuccinate for improving the foam stability of a cosmetic composition.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Abstract: The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.

Abstract: The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Provided herein are chelator constructs (e.g., nucleic acid, peptide, peptide nucleic acid, etc.) that sequester metal ions (e.g., Mg2+) under a first set of conditions and fail to sequester or release sequestered metal ions under a second set of conditions. In particular, nucleic acid constructs are provided that sequester metal ions (e.g., Mg2+) under conditions that favor secondary and tertiary structure formation and release or fail to sequester metal ions under conditions that disfavor the formation of such structures.

Abstract: Materials, methods, and systems for determining the sequence of a target nucleic acid are disclosed and described. Materials can include ssDNA, ssRNA, and dsDNA. Materials are first transformed to partially or fully osmylated single-stranded nucleic acid (osmylated or labeled polymer) after reaction with Osmium tetroxide 2,2?-bipyridine which labels selectively Thymidine over Cytidine, but leaves purines intact. Methods are provided to describe preparation of the osmylated polymers, their purification, and characterization. Labeled polymers are subject to voltage-driven translocation via nanopores of appropriate width so that the polymer can traverse as a single-file. The translocation is monitored and reported as a current vs. time (i-t) profile. The current is stable, but fluctuates during the polymer's translocation in a manner that pinpoints the osmylated bases interspersed among the intact bases.

Abstract: The present invention relates to oxysterols of formula (I) for use in the treatment of infections caused by a naked virus, in particular a virus selected from the group consisting of rotavirus, papillomavirus and rhinovirus.

Abstract: A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. Medical devices can be made incorporating the ceragenin compound.

Abstract: Novel synthesized amino acids of glutamine and lysine that are directly PEGylated with small, monodisperse PEGs, and a novel process for creating novel amino acid monomers using PEGylation. These amino acids are readily incorporated into peptides for a range of different applications.

Abstract: The present invention is directed to affinity chromatography devices that separate a targeted protein or antibody from an aqueous mixture containing the targeted protein or antibody. The chromatography device may contain a stacked membrane assembly or a wound membrane assembly. The membrane assemblies include (1) at least one polymer membrane that contains therein inorganic particles and (2) at least one impermeable layer (e.g., a thermoplastic polymer in a solid state). The polymer membrane and/or the inorganic particles have an affinity ligand bonded thereto. The affinity ligand may be a protein, an antibody, or a polysaccharide that reversibly binds to the targeted protein or antibody. The chromatography device may be repeatedly used and may be cleaned with a caustic solution between uses. The chromatography devices has a dynamic binding capacity (DBC) of at least 30 mg/ml (or 0.07 micromol/ml) at 10% breakthrough at a residence time of 20 seconds or less.

Abstract: The present invention relates to the cationic lipid cordiaroimide hybrid compounds of formula I. The present invention provides a process for preparation of these compounds is also being elaborated. The compounds described provides anticancerous activity against cell lines including PC-3 (prostate cancer), HepG2 (liver cancer), MCF-7 (breast cancer) and NIH-1/3T3 (non cancer cells. The compound was also capable of inducing caspase-3 mediated apoptosis in HepG2 cells by arresting the cell cycle in the G1 phase. Furthermore, the compound exhibited DNA ligase I inhibition. The present class of cationic lipid cordiarimide hybrids is likely to find specific use in developing novel targeted therapies for liver and prostate cancers.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: Provided herein is a novel epitope that can be used as a tag in methods for rapid and effective characterization, purification, and subcellular localization of polypeptides of interest, which comprise the tag. The tag is specifically recognized by an epitope specific antibody, which can be used to detect, capture, quantify, and/or purify polypeptides of interest that are tagged with the epitope. Also provided is novel epitope specific antibody.

Abstract: The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.

Abstract: This invention relates to NK cell activation and NK cell mediated immunity, immunogenic peptides, compositions and complexes; and associated methods of treatment or prophylaxis. In particular, a peptide capable of activating NK cell-mediated immunity, the peptide comprising or consisting of the amino acid sequence XnAX2X1 wherein Xn is an amino acid sequence of between 5 and 12 residues, and X1 is any amino acid; or leucine or isoleucine; and X2 is alanine, threonine, tryptophan, or serine.

Abstract: Provided herein is a novel epitope that can be used as a tag in methods for rapid and effective characterization, purification, and subcellular localization of polypeptides of interest, which comprise the tag. The tag is specifically recognized by an epitope specific antibody, which can be used to detect, capture, quantify, and/or purify polypeptides of interest that are tagged with the epitope. Also provided is novel epitope specific antibody.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.

Abstract: The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel Kv1.3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.

Abstract: The invention relates to a peptide dendrimer described by a general formula X—(B2—[Y2]S-D1)2-B1—Z, wherein X is (D2)4 or (D3)8-(B3—[Y3]r-D2)4 or a higher analogue, Y is a linkage moiety, Z is a central moiety; each B denotes a diaminoalkylcarboxylic acid moiety; each D is a hydrophobic or cationic amino acid, or a di- or tripeptide composed of hydrophobic and cationic amino acids, for use as a pharmaceutical.

Abstract: The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.

Abstract: Disclosed is a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labelling particles, e.g. proteins, or surfaces, which is capable of binding reversibly a fluorogenic chromophore of formula (I), and which is capable of enhancing the brightness of the fluorogenic chromophore upon complexation thereto; and of inducing the spectral shift of the fluorogenic chromophore through the ionization of an auxochromic group thereof.

Abstract: A general method and strains of bacteria are described by means where the endogenous DNAK protein or homolog of the DNAK protein is tagged with a recognizable amino acid sequence and that through this tag, DNAK may be efficiently removed, and as such, recombinant protein purification may be greatly improved both in yield and purity with simplified purification steps that remove the DNAK and reduced cost, waste accumulation and labor, and the isolated recombinant protein will significantly benefit research and therapeutics in its application.

Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.